The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global blood plasma derivatives market reached a value of US$ 40.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 59.8 Billion by 2027, exhibiting a CAGR of 6.40% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Blood plasma derivatives are concentrates of specific proteins prepared from plasma that are obtained through fractionation process. Factor VIII, immunoglobulin, albumin, hyperimmune globulin, factor IX and fresh frozen are some of the common blood plasma derivatives. They are rich in proteins, minerals, salts, hormones, vitamins and protease inhibitors, due to which they are widely used to kill viruses that cause hepatitis B, hemophilia A, bleeding disorders, immunodeficiency, hepatitis C, hypogammaglobulinemia, hemophilia B and human immunodeficiency virus (HIV). Apart from this, blood plasma derivatives assist in enhancing nutrition, controlling body temperature and coagulation of blood, maintaining osmotic pressure, enhancing respiration and excretion, and regulating acid-base balance. Blood plasma derivatives are commonly stored at hospitals, clinics, diagnostic centers and blood transfusion centers.
The increasing geriatric population that are more susceptible to developing infectious diseases are creating a positive outlook for the market. Blood plasma contains immunoglobulins that play an important role in the development of immunity and maintain the osmotic pressure in blood vessels, which further prevents the onset immunodeficiency disorders and hemophilia. Moreover, the widespread product adoption to treat coronavirus disease (COVID-19) patients by convalescent plasma treatment is favoring the market growth. Additionally, various technological innovations in the fractionation process that aids in separating protein concentrates and various components of blood plasma for clinical purposes are providing a considerable boost to the market growth. In line with this, the development of advanced preservation methods, along with the significant improvements in encased procedures for developing targeted therapeutic products are further augmenting the market growth. Other factors, including significant growth in the healthcare industry, increasing awareness regarding blood and plasma donation and the implementation of various government initiatives to promote blood donation camps, are anticipated to drive the market further toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global blood plasma derivatives market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, application and end user.
Breakup by Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Bayer AG, CSL Limited, Fusion Health Care Pvt. Ltd., Grifols S.A., Kedrion S.p.A., LFB S.A., Octapharma AG, Sanofi S.A. and Takeda Pharmaceutical Company Limited.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Baxter International Inc., Bayer AG, CSL Limited, Fusion Health Care Pvt. Ltd., Grifols S.A., Kedrion S.p.A., LFB S.A., Octapharma AG, Sanofi S.A. and Takeda Pharmaceutical Company Limited.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global blood plasma derivatives market was valued at US$ 40.5 Billion in 2021.
We expect the global blood plasma derivatives market to exhibit a CAGR of 6.40% during 2022-2027.
Extensive R&D activities for understanding the potency of blood plasma products in several therapeutic treatments, including immunology, oncology, pulmonology, rheumatology, neurology, etc., are primarily driving the global blood plasma derivatives market.
The sudden outbreak of the COVID-19 pandemic has led to the growing adoption of blood plasma derivatives to treat the patients suffering from the coronavirus infection, thereby positively influencing the market growth.
Based on the type, the global blood plasma derivatives market has been segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. Among these, immunoglobulin currently holds the majority of the total market share.
Based on the end-user, the global blood plasma derivatives market can be divided into hospitals, clinics, and others. Currently, hospitals exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global blood plasma derivatives market include Baxter International Inc., Bayer AG, CSL Limited, Fusion Health Care Pvt. Ltd., Grifols S.A., Kedrion S.p.A., LFB S.A., Octapharma AG, Sanofi S.A., and Takeda Pharmaceutical Company Limited.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at